Simultaneous Liver and Heart Transplantation in Patients With Familial Amyloid Polyneuropathy

Trasplante hepático y cardiaco simultáneo en pacientes con polineuropatía amiloidótica familiar

Introduction

Familial amyloid polyneuropathy (FAP) is a dominant autosomal disease that is progressive and fatal. It is characterised by deposits of transthyretin (TTR), a protein that is predominantly synthesised in the liver, and clinical manifestations depend on the type of organ involved. Cardiac involvement presents as a restrictive cardiomyopathy, which is the main cause of morbidity and mortality. The only effective treatment is liver transplantation (LT); meanwhile, in patients who present important cardiac involvement, lung and heart transplantation are indicated. We present our experience with 2 cases of simultaneous heart and liver transplantation due to FAP.

Case 1

The patient is a 61-year-old woman from the Canary Islands with a family history of FAP diagnosis. In 2002, her symptoms began with weight loss and paraesthesia. A genetic study demonstrated the presence of the Glu89Lys mutation, which provided the diagnosis of FAP. Echocardiogram detected restrictive cardiomyopathy. Abdominal CT and ultrasound were normal. Serology was negative.

In January 2005, heart transplantation was performed by means of the Lower-Shumway–Barnard technique, which was followed by LT using the inferior vena cava preservation technique, without bypass. In addition, a domino transplantation was carried out without incident. The pathology study of the heart reported primary amyloidosis. Postoperative evolution was favourable. The postoperative echocardiogram demonstrated left and right ventricles that were not dilated and preserved systolic function. The patient was discharged 24 days posttransplantation.

Currently, the patient is alive and continues to have adequate hepatic and cardiac function 9 years after the combined transplantation. Her mobility is reduced to an armchair-to-bed range due to the advanced stage of her disease at the time of transplantation.

REFERENCES


Izaskun del Hoyo Aretxabala*, Pilar Gómez García, M. Inmaculada Concepción Cruz González, Sandra Ruiz Carballo, Iñaki Iturburu Belmonte

Unidad de Cirugía Hepatobiliar-Pancreática, Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain

*Corresponding author.
E-mail address: izaskun.delhoyoaretxabala@osakidetza.net
(I. del Hoyo Aretxabala).

2173-5077/
© 2014 AEC. Published by Elsevier España, S.L.U. All rights reserved.
alterations, so it was used for domino transplantation. The patient was discharged 17 days post-transplantation and showed good progress. Histologic analysis of the endomyocardial biopsy demonstrated transthyretin-positive amyloid deposits.

Seven years after heart/liver transplantation, the patient has good hepatic and cardiac function, no signs of neurologic progression and LV with normal systolic function (LVEF 74%).

Tables 1 and 2 show the clinical, demographic and perioperative characteristics of the patients in our series who underwent simultaneous heart and liver transplantation.

### Discussion

The first combined liver and heart transplantation was published in 1984 by Starzl et al. By 2013, 143 combined heart/liver transplantations had been reported, with operative mortality rates that ranged between 0 and 25%. The surgical options that are discussed in this procedure are the following: (1) heart transplantation and LT several months afterwards; (2) heart transplantation followed by LT within the same operation after chest closure; and (3) heart transplantation followed by LT while the heart is being reperfused in cardiopulmonary bypass.

The sequential approach poses a risk for cardiac amyloid deposits while waiting for LT; in addition, the fact that the patient receives 2 grafts from different donors could lead to immunological problems. The simultaneous approach presents disadvantages such as bleeding, coagulopathy and prolonged surgical times. In fact, Shaw et al. reported that induced coagulopathy took several hours for reversal. In our series, the sequence of the combined technique was, first of all, heart transplantation with extracorporeal circulation (EC). After this procedure, EC was disconnected, heparin was neutralized and the chest was then closed; subsequently, LT was initiated. This type of approach provides adequate haemodynamic control after heart transplantation and, although it meant a significant increase in liver ischaemia time, this did not influence the recovery of graft function.

The presence of 2 organs in one recipient, whether or not they come from the same donor, poses special immunological problems. The liver seems to play a protective immunological role when the transplantation is done in combination with other organs, so there is a lower incidence of rejection and greater survival than in cases of solitary extrahepatic organs.

In conclusion, combined heart/liver transplantation is indicated in patients who present severe cardiac dysfunction and FAP. The induction of the tolerance of the liver to other extrahepatic organs promotes a lower incidence of rejection and greater survival of transplanted hearts.

### References


Servicio de Cirugía General «C» y Trasplante de Órganos Abdominales, Hospital Universitario 12 de Octubre, Madrid, Spain

*Corresponding author.
E-mail address: alejandro_mq@yahoo.es (A.A. Marcacuzco Quinto).

2173-5077/ © 2015 AEC. Published by Elsevier España, S.L.U. All rights reserved.